The global sales of closed system transfer devices are estimated to be worth USD 1,028.8 million in 2024 and anticipated to reach a value of USD 2,283.5 million by 2034. Sales are projected to rise at a CAGR of 8.3% over the forecast period between 2024 and 2034. The revenue generated by closed system transfer devices in 2023 was USD 949.9 million.
Health care professionals, especially those involved in the preparation and delivery of hazardous drugs, are in danger of being exposed to life-threatening materials. Specialty practices involving oncology become particularly precarious because cytotoxic drugs are more frequently used.
The new technologies also provide a very viable means for solving this problem by reducing the possibility of contamination of drugs and exposure to them, thereby becoming an integral part of the safety protocols in health care environments.
Global Closed System Transfer Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 949.9 million |
| Estimated Size, 2024 | USD 1,028.8 million |
| Projected Size, 2034 | USD 2,283.5 million |
| Value-based CAGR (2024 to 2034) | 8.3% |
Hazardous drugs, in particular chemotherapeutic agents, have been described as causing carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity, and genetic toxicity. While these drugs obviously are agents which health care workers handle routinely, the potential exists for drug exposure to occur via inhalation, through skin contact, or by accidental ingestion or needlesticks.
Small amounts of repeated exposures may lead, over time, to serious health results, including cancers, reproductive results, and other chronic diseases.
While National Institute for Occupational Safety and Health, Occupational Safety and Health Administration, and United States Pharmacopeia have developed standards for safe handling of hazardous drugs in healthcare settings, for instance, USP <800> guides on how hazardous drugs are managed in healthcare premises concerning the adoption of CSTDs to allow closed, secured systems that prevent drugs' leakage and aerosolization.
The design of CSTDs is to mechanically prevent the transfer of environmental contaminants into the system and inhibit the escape of hazardous drug or vapor concentrations outside the system.
Health institutions, driven by needs to comply with regulatory requirements and safeguard their staff, are increasingly adopting CSTDs in their practice. Safety policies have made CSTDs part of many hospitals and oncology centers alike whose preparation and administration involve hazardous drugs.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The below table presents the expected CAGR for the global closed system transfer devices market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 9.3%, followed by a slightly lower growth rate of 8.9% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 9.3% (2023 to 2033) |
| H2 | 8.9% (2023 to 2033) |
| H1 | 8.3% (2024 to 2034) |
| H2 | 7.9% (2024 to 2034) |
The above table presents the expected CAGR for the global closed system transfer devices market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 9.3%, followed by a slightly decline in growth rate of 8.9% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 8.3% in the first half and increase moderately at 7.9% in the second half. In the first half (H1) the market witnessed an decrease of 100.00 BPS while in the second half (H2), the market witnessed a decrease of 100.00 BPS.
The Rising Incidence of Cancer Globally Is Significantly Driving the Closed System Transfer Devices Market
As cancer rates continue to increase, so does the demand for chemotherapy and other treatments that involve hazardous drugs. This surge in cancer cases necessitates enhanced safety measures to protect healthcare workers from the risks associated with handling these potent medications.
Cancer is one of the leading causes of morbidity and mortality globally, with millions of new cases diagnosed each year. According to the Centers for Disease Control and Prevention (CDC): In 2021, new cancer cases were reported as 1,777,566 in the United States. In 2022, there were 608,366 deaths caused by cancer in the United States.
The increasing prevalence of cancer have been linked to the factors that comprise an aging population, lifestyle changes, and exposure to various environmental substances. It places a higher demand on chemotherapy drugs and other dangerous treatments if there are high rates of increased prevalence. This plays a very significant role in managing and treating cancer but poses ample risks to those dealing with these chemicals.
The CSTDs are designed such that the devices address the whole gamut of safety challenges associated with hazardous drugs. These devices create a closed environment while preparing, transferring, and administering chemotherapy drugs, in effect preventing escape of drug vapors and aerosols into the surrounding environment.
CSTDs minimize risks from hazardous drug exposure, hence protecting healthcare workers and building up safety in oncology and other areas. This correlation also demonstrates the rise in market demand for CSTDs as a result of the increased incidence of cancer, therefore making such devices significant in modern health care.
The Increasing Use of Hazardous Drugs Complex Medical Conditions Is Propelling the Demand for Closed System Transfer Devices
The increasing prevalence of cancer, autoimmune disorders, and other chronic diseases is increasing administration of potent and often toxic medications including chemotherapy drugs, monoclonal antibodies, and anti-viral medications. Such hazardous drugs have benefit to the patients but put healthcare workers who handle them at great risk, hence making closed system transfer devices a necessary safety solution in medical practice.
Chemotherapy drugs are highly toxic, and exposure to these drugs can be carcinogenic, teratogenic, and cause organ toxicity to the person handling drugs. Other hazardous drugs in increasing use include those used to treat autoimmune diseases-immunosuppressants, and HIV/AIDS-antiretrovirals-also increases the demand for their safe handling.
The significant increase in volume of chemotherapy drugs handeling has increased rate of incidence. It is the increased incidences that have raised the demand to provide proper protection to health care workers against any accidental exposure while preparing, transporting and administering toxic drugs.
Cisplatin, Cyclophosphamide, and Doxorubicin are a few examples of some of the most common drugs applied in chemotherapy to treat cancer diseases. These drugs are highly toxic and present serious health effects if preparation and administration expose health workers to them.
For example, accidental exposure of workers to cyclophosphamide has been associated with an increased risk of secondary cancers and reproductive toxicity. Examples of such CSTDs include BD PhaSeal System. These devices play a crucial role in protecting healthcare workers from exposure to toxic substances.
The Increasing Focus On the Prevention of Cross-Contamination in Healthcare Settings Is a Significant Driver
Cross-contamination is defined as the transmission of undesirable or harmful substances into a patient or an environment by organisms, hazardous drugs, or chemicals. The spreading of hazardous drugs can be avoided in settings that routinely handle hazardous drugs, such as hospitals and oncology clinics, or pharmacies, and these should be kept safe from cross-contamination for patients and staff members and the healthcare environment as a whole.
Such hazardous drugs, including immunosuppressants, and antivirals, present health problems in cases of surface, medical equipment, or air contamination in healthcare facilities. Even at low levels of exposure, adverse health effects include skin rashes, reproductive problems, and increased secondary cancers among health care workers.
United States Pharmacopeia Chapter 800 presents requirements for safe handling of hazardous drugs that protect healthcare personnel, patients, and the environment from unnecessary exposure. Among others, this chapter outlines conditions relative to the implementation of CSTDs in order to avoid cross-contamination upon compounding and administering hazardous drugs.
The increasing emphasis on the prevention of cross contamination in health facilities provides a strong boost for the CSTDs market. It is for this reason that CSTDs have emerged as an efficient method of keeping hazardous drugs in a closed system. This prevents accidental exposure to healthcare workers and patients and maintains a sterile environment.
Dearth of Awareness and Training is a Significant Restraint in The Widespread Adoption of Closed System Transfer Devices.
Closed system transfer devices are typically sophisticated devices that incorporate complex mechanisms for self-sealing valves, air-tight chambers, and needle-free connections. Although these features enhance safety, they concurrently require specific handling techniques to ensure the integrity of the closed system.
A large component of handling CSTDs safely involves proper training for health care professionals, including pharmacists, nurses, and technicians, in many areas of CSTD use: proper methods of assembly, appropriate techniques of drug transfer, and safety in disconnection. These can be quite extensive, given that, in addition to the initial training, refresher courses are also held from time to time to keep your personnel proficient in handling these devices.
Even in ideal training conditions, state-of-practice compliance with protocols regarding CSTD usage is hard to attain. Human error, variable practice, and time pressures amidst the fast-paced environment of healthcare may result in incorrect handling of the CSTD.
This includes partial engagement of the device, improper handling during the transfer of the drug, and improper disconnection, which might result in compromise of the closed system and increased hazardous drug exposure.
The risk of exposure is high hence, strict trainings required for the devices, and other implications of non-compliance can also pose a limit to the full integration of CSTDs in healthcare facilities.
Principal Consultant
The global closed system transfer devices industry recorded a CAGR of 6.1% during the historical period between 2019 and 2023. The growth of closed system transfer devices industry was positive as it reached a value of USD 949.9 million in 2023 from USD 693.5 million in 2019.
Closed system transfer devices have changed the market dynamics, mainly for reasons of ensuring safety with the handling of hazardous drugs. Prior to the introduction of modern CSTDs in clinical settings, basic methods of drug handling, such as manual preparation and traditional systems of needles and syringes, were the common practices.
However, these previous methods were insufficient to prevent hazardous drugs exposure to healthcare professionals, creating major health problems and leading to concerns regarding contamination and accidents.
This was followed by the actual construction of the first generation of CSTDs, providing simple mechanical barriers, such as the addition of physical barriers and filters to prevent the hazardous drug vapors and aerosols from escaping.
With the various technological advances, the future of the Closed System Transfer Devices market is bright and will be better positioned to guarantee safety in medical settings. Future CSTDs should have innovative features aimed at improving usability and further streamlining the process, hence enhancing efficiency and overall drug handling safety.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 53.7% in global market. These companies focus on innovative product development by investing heavily in research and development to enhance the functionality, safety, and ease of use of their CSTDs.
This includes integrating advanced technologies such as smart monitoring systems and user-friendly designs. Prominent companies in tier 1 include Baxter, B. Braun SE and BD.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 29.7% market share. These companies often target niche segments within the market, such as specific types of hazardous drugs or particular healthcare settings (e.g., oncology clinics).
By specializing in other areas, they differentiate themselves from larger competitors. Prominent companies in tier 2 include ICU Medical, Inc, EQUASHIELD and Corvida Medical.
Finally, Tier 3 companies, such as Caragen Ltd, and JMS Co.Ltd. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the closed system transfer devices market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 9.2% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 2.5% |
| China | 8.1% |
| France | 4.1% |
| India | 9.2% |
| Germany | 2.6% |
| Spain | 4.7% |
| Australia | 3.7% |
| South Korea | 6.4% |
China closed system transfer devices market is poised to exhibit a CAGR of 8.1% between 2024 and 2034. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
The Chinese government has emphasized healthcare reform and ensured access to advanced medical technologies, thus facilitating the adoption of safety measures such as CSTD to avoid hazardous drug exposure among healthcare workers.
In addition, China has a strong manufacturing base that enables the production of CSTDs at low costs, thus opening up greater accessibility for these devices to both domestic and international markets. Appealing prices for quality medical devices fabricated in the country attract worldwide buyers who seek a reliable solution to handle drugs effectively.
USA closed system transfer devices market is poised to exhibit a CAGR of 3.1% between 2024 and 2034. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
The leading position of the USA in the North American market is highly contributed by the presence of CSTD manufacturing companies in the country. Similarly, the USA is a base of various leading companies such as B. Braun Medical Inc., ICU Medical, BD, and EQUASHIELD, among others that offer a wide range of innovative and qualitative products to ensure greater safety while handling hazardous drugs.
Increasingly, the advantages of minimal exposure risk associated with hazardous drugs have been driving health facilities to demand CSTDs. A strong manufacturing presence, along with regulatory support and an emphasis on safety, is placing the USA in an advantageous position for strong growth in the CSTD market in North America during the forecast period.
The closed system transfer devices market is expected rise at a CAGR of 9.2% within the forecasted period from 2024 to 2034. Currently, India has prominent share in the market of the Asia Pacific, and the trend is likely to continue during the forecast period.
With the increasing burden of cancer and other chronic diseases in India, demands have risen for effective closed system transfer devices that offer safer oncology practice. There is on the basis of increased incidence of cancers due to changes in lifestyle and environment, and aging, which in turn has seen the number of chemotherapy treatments rise.
The fast-developing health care system in India has to embrace CSTDs implemented in chemotherapy procedures in order to decrease probable exposures among professional workers and patients alike.
CSTDs provide the level of protection against the hazardous effects of chemotherapy drugs that can, if handled negligently, introduce grave health risks. These are increasingly being recognized within the Indian healthcare sector and leading to a cultural shift toward the adoption of measures that protect both patients and medical staff.
The section contains information about the leading segments in the industry. By product the systems segment holds the highest market share of 62.6% in 2024.
| By Product | Systems |
|---|---|
| Value Share (2024) | 62.6% |
The dominant segment of the closed system transfers devices market has emerged as systems, consisting of needle-free injection and needle systems. This leading position can be attributed to the fact that these systems play a critical role in keeping in view that CSTDs prevent an exposure risk of hazardous drugs to healthcare workers in order to enable the safe handling of such drugs.
Needle-Free Systems are a sub-segment of systems that growing fast due to advanced safety features and user convenience. These systems eliminate needles, thereby reducing the chance of needlestick injuries-one of the most prevalent risks among health professionals handling hazardous drugs.
| By Application | Nursing |
|---|---|
| Value Share (2024) | 42.5% |
The nurses are considered to be on the frontline in medication handling in different health facilities like hospitals, outpatient clinics, and chemotherapy centers. Their role includes the preparation of medications accurately and the administration of those medications safely, especially dangerous medications such as chemotherapy agents and some kinds of antibiotics.
Due to the high risk of exposure with these drugs, closed system technology has become an indispensable part of nursing practice in protecting both healthcare personnel and patients from possible contamination and other adverse effects. Besides that, growing concern for workplace safety and the requirement for strict compliance with regulatory demands have also contributed to driving the demand for closed systems in nursing applications.
Thus, the high share of the nursing application segment in the Closed System market can be explained by the high requirements for the safety solutions of this sector. Nursing has also remained one of the important drivers of the market's expansion, caused by the continuous growth of the demand to handle drugs safely and efficiently while taking care of patients with greater efficiency.
Market players are using different strategies in order to stay competitive in their respective markets, such as with innovative formulations, differentiation of products, and through strategic tie-ups with healthcare providers in an effort to increase distribution. Other key strategic areas of focus for these companies would be an active search for strategic partners that will further reinforce their product portfolios and increase their global market presence.
Recent Industry Developments in Closed System Transfer Devices Market
In terms of product, the industry is divided systems (needle free systems and needle systems) and components (vial adaptors, syringe adaptors and tubing sets and accessories).
In terms of application, the industry is segregated into- pharmacy, nursing and veterinary.
In terms of distribution channel, the industry is segregated into- direct sales and distributors.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global closed system transfer devices market is projected to witness CAGR of 8.3% between 2024 and 2034.
The global closed system transfer devices industry stood at USD 949.9 million in 2023.
The global closed system transfer devices market is anticipated to reach USD 2,283.5 million by 2034 end.
India is set to record the highest CAGR of 9.2% in the assessment period.
The key players operating in the global closed system transfer devices market include ICU Medical, Inc., Baxter, B. Braun Melsungen AG, BD, EQUASHIELD, Corvida Medical, Yukon Medical, Caragen Ltd. and JMS Co. Ltd.
Explore Healthcare Insights
View Reports
Closed System Transfer Devices Market
